Phase 4 Liver Cancer Trial, Recruiting NCT07405086 Sponsor: OHSU Knight Cancer Institute Condition: Liver Cancer
Back to Liver Cancer

Phase 4 Liver Cancer Trial, Recruiting

NCT07405086
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are willing and able to sign a written consent form before any study procedures begin
  • People aged 18 years or older
  • People who have been diagnosed (through laboratory tissue testing) with an advanced or spreading solid tumour that is one of the following types: non-small cell lung cancer (without certain gene mutations, and suitable for immune therapy), head and neck squamous cell carcinoma (that has returned or spread, and suitable for platinum-based treatment), kidney cancer, biliary tract cancer (affecting the bile ducts or gallbladder), liver cancer (hepatocellular carcinoma), or melanoma
  • People whose treating doctor has planned for them to receive an FDA-approved immune checkpoint inhibitor — a type of cancer treatment that works through the immune system — for their cancer
  • People whose cancer can be measured on scans according to a standard medical measurement system called RECIST 1.1

Who may not be able to join:

  • People who have previously received immune checkpoint inhibitor treatment for their cancer
  • People who are currently using, or have used within the past 28 days, medications that suppress the immune system — with some exceptions for low-dose steroid inhalers, nasal sprays, or very low-dose steroid tablets (confirm with trial site)
  • People who have an autoimmune condition (where the immune system attacks the body) that is not well controlled and requires immune-suppressing treatment
  • People who have cancer that has spread to the brain or spinal cord and is not currently under control

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
OHSU Knight Cancer Institute
Registry
ClinicalTrials.gov
Start date
8 June 2026
Est. completion
31 December 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Progression free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov